PriceTargets.com logo

Pfizer - PFE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $32.14
  • Forecasted Upside: 21.94%
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 9 Hold Ratings
  • 5 Buy Ratings
  • 2 Strong Buy Ratings
$26.36 As of 12/20/2024 06:45 PM ET
▲ +0.59 (2.29%)

This chart shows the closing price for PFE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pfizer Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PFE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PFE

Analyst Price Target is $32.14
▲ +21.94% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is $32.14, with a high forecast of $45.00 and a low forecast of $25.00. The average price target represents a 21.94% upside from the last price of $26.36.

This chart shows the closing price for PFE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 17 polled investment analysts is to hold stock in Pfizer. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 2 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024Truist FinancialLower TargetBuy ➝ Buy$36.00 ➝ $32.00
12/11/2024GuggenheimLower TargetBuy ➝ Buy$35.00 ➝ $33.00
12/10/2024Bank of AmericaReiterated RatingNeutral$29.00
11/15/2024Wolfe ResearchInitiated CoverageUnderperform$25.00
10/30/2024Evercore ISIUpgradeStrong-Buy
10/25/2024CitigroupInitiated CoverageNeutral$30.00
10/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
10/17/2024Sanford C. BernsteinInitiated CoverageMarket Perform$32.00
10/3/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
8/19/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
8/7/2024Daiwa AmericaUpgradeModerate Buy ➝ Strong-Buy
8/7/2024Daiwa Capital MarketsUpgradeNeutral ➝ Outperform$28.00 ➝ $34.00
7/31/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$30.00 ➝ $32.00
7/31/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$28.00 ➝ $30.00
7/31/2024UBS GroupBoost TargetNeutral ➝ Neutral$30.00 ➝ $31.00
7/31/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
7/10/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$28.00 ➝ $30.00
7/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
6/26/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
6/17/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00
5/2/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$28.00 ➝ $29.00
5/2/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$33.00 ➝ $36.00
4/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00
3/22/2024ArgusDowngradeBuy ➝ Hold
3/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00
2/23/2024GuggenheimInitiated CoverageBuy$36.00
1/31/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00
1/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$45.00
1/4/2024TD CowenDowngradeOutperform ➝ Market Perform$32.00
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
12/14/2023Truist FinancialLower TargetBuy ➝ Buy$42.00 ➝ $36.00
12/14/2023UBS GroupLower TargetNeutral ➝ Neutral$34.00 ➝ $27.00
12/14/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$34.00 ➝ $28.00
12/4/2023Truist FinancialReiterated RatingBuy ➝ Buy$42.00
11/20/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00
11/1/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$35.00 ➝ $34.00
11/1/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$39.00 ➝ $37.00
10/20/2023UBS GroupReiterated RatingNeutral ➝ Neutral$36.00 ➝ $34.00
10/17/2023Truist FinancialLower TargetBuy ➝ Buy$62.00 ➝ $42.00
10/17/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$40.00 ➝ $39.00
10/16/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$44.00 ➝ $33.00
10/16/2023CitigroupLower TargetNeutral ➝ Neutral$42.00 ➝ $35.00
10/16/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$36.00 ➝ $34.00
10/16/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$39.00 ➝ $35.00
10/16/2023Jefferies Financial GroupUpgradeHold ➝ Buy$38.00 ➝ $39.00
10/6/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$39.00 ➝ $36.00
10/2/2023BarclaysLower Target$38.00 ➝ $35.00
10/2/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00
9/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00
9/13/2023Truist FinancialReiterated RatingBuy ➝ Buy$62.00
9/5/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00
8/30/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00
8/2/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$45.00 ➝ $44.00
8/2/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$42.00 ➝ $40.00
8/2/2023Truist FinancialLower TargetBuy ➝ Buy$64.00 ➝ $62.00
8/2/2023Jefferies Financial GroupLower Target$40.00 ➝ $38.00
7/21/2023Morgan StanleyLower TargetEqual Weight$43.00 ➝ $42.00
7/18/2023BMO Capital MarketsLower Target$49.00 ➝ $45.00
7/17/2023JPMorgan Chase & Co.Lower TargetNeutral$45.00 ➝ $41.00
7/14/2023HSBCInitiated CoverageBuy$50.00
7/11/2023BarclaysLower Target$40.00 ➝ $38.00
6/29/2023Credit Suisse GroupDowngradeOutperform ➝ Neutral$47.00 ➝ $40.00
5/17/2023Cantor FitzgeraldReiterated RatingOverweight
5/11/2023Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$38.00
5/5/2023UBS GroupLower Target$41.00 ➝ $39.00
5/3/2023BarclaysLower Target$43.00 ➝ $40.00
4/21/2023Bank of AmericaLower TargetNeutral$50.00 ➝ $45.00
4/12/2023BarclaysLower TargetEqual Weight$44.00 ➝ $43.00
4/10/2023Morgan StanleyLower TargetEqual Weight$45.00 ➝ $44.00
3/17/2023Wells Fargo & CompanyLower TargetEqual Weight$50.00 ➝ $44.00
3/14/2023UBS GroupSet Target$45.00
3/6/2023Jefferies Financial GroupInitiated CoverageHold$43.00
2/28/2023UBS GroupSet Target$45.00
2/27/2023JPMorgan Chase & Co.Set Target$45.00
2/7/2023Berenberg BankSet Target$40.00
2/7/2023Daiwa Capital MarketsUpgradeNeutral ➝ Outperform$51.00
2/1/2023UBS GroupSet Target$45.00
2/1/2023Morgan StanleyLower TargetEqual Weight$53.00 ➝ $45.00
2/1/2023Cantor FitzgeraldReiterated RatingOverweight$75.00
2/1/2023Leerink PartnersLower TargetMarket Perform$49.00 ➝ $48.00
2/1/2023Atlantic SecuritiesLower TargetNeutral$50.00 ➝ $46.00
2/1/2023BMO Capital MarketsLower TargetOutperform$55.00 ➝ $53.00
2/1/2023Credit Suisse GroupLower TargetOutperform$54.00 ➝ $50.00
2/1/2023BarclaysLower TargetEqual Weight$49.00 ➝ $44.00
1/31/2023JPMorgan Chase & Co.Set Target$50.00
1/26/2023UBS GroupDowngradeBuy ➝ Neutral$55.00 ➝ $47.00
1/18/2023UBS GroupSet Target$55.00
1/18/2023Credit Suisse GroupSet Target$54.00
1/18/2023JPMorgan Chase & Co.Set Target$50.00
1/17/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$54.00 ➝ $50.00
1/10/2023JPMorgan Chase & Co.Set Target$50.00
1/4/2023Bank of AmericaDowngradeBuy ➝ Neutral$60.00
12/14/2022Morgan StanleyBoost TargetEqual Weight$51.00 ➝ $53.00
12/13/2022Credit Suisse GroupSet Target$55.00
12/13/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$47.00 ➝ $60.00
12/6/2022Credit Suisse GroupSet Target$55.00
11/23/2022Credit Suisse GroupSet Target$55.00
11/17/2022Credit Suisse GroupInitiated CoverageOutperform$55.00
11/8/2022The Goldman Sachs GroupSet Target$47.00
11/3/2022Leerink PartnersBoost TargetMarket Perform$48.00 ➝ $49.00
11/3/2022UBS GroupSet Target$55.00
11/2/2022Wells Fargo & CompanyLower TargetOverweight$55.00 ➝ $54.00
11/2/2022Morgan StanleyBoost TargetEqual Weight$50.00 ➝ $51.00
11/2/2022BarclaysBoost TargetEqual Weight$44.00 ➝ $49.00
11/1/2022JPMorgan Chase & Co.Set Target$50.00
10/17/2022The Goldman Sachs GroupSet Target$48.00
10/12/2022Morgan StanleyBoost TargetEqual Weight$49.00 ➝ $50.00
10/12/2022BarclaysLower TargetEqual Weight$50.00 ➝ $44.00
10/11/2022JPMorgan Chase & Co.Set Target$50.00
10/11/2022Leerink PartnersLower TargetMarket Perform ➝ Market Perform$53.00 ➝ $48.00
9/14/2022Berenberg BankSet Target$44.00
9/1/2022The Goldman Sachs GroupSet Target$50.00
9/1/2022UBS GroupSet Target$59.00
9/1/2022BarclaysSet Target$50.00
8/26/2022The Goldman Sachs GroupSet Target$50.00
8/26/2022UBS GroupSet Target$59.00
8/26/2022BarclaysSet Target$50.00
8/9/2022BarclaysBoost Target$52.00
8/1/2022BarclaysBoost TargetEqual Weight$50.00 ➝ $52.00
7/29/2022The Goldman Sachs GroupSet Target$50.00
7/29/2022Leerink PartnersLower TargetMarket Perform$55.00 ➝ $53.00
7/13/2022The Goldman Sachs GroupSet Target$51.00
7/8/2022Morgan StanleyLower TargetEqual Weight$52.00 ➝ $49.00
7/7/2022BarclaysSet Target$52.00
6/28/2022JPMorgan Chase & Co.Set Target$57.00
6/27/2022BarclaysSet Target$52.00
5/27/2022Berenberg BankSet Target$50.00
5/25/2022The Goldman Sachs GroupSet Target$51.00
5/23/2022Leerink PartnersInitiated CoverageMarket Perform$55.00
5/19/2022Berenberg BankSet Target$50.00
5/17/2022BarclaysSet Target$52.00
5/4/2022BarclaysSet Target$52.00
5/4/2022The Goldman Sachs GroupSet Target$51.00
5/4/2022Wells Fargo & CompanyLower Target$60.00 ➝ $55.00
5/3/2022JPMorgan Chase & Co.Set Target$57.00
4/21/2022Berenberg BankSet Target$50.00
4/6/2022Morgan StanleyInitiated CoverageEqual Weight$55.00
4/5/2022CitigroupBoost TargetNeutral$46.00 ➝ $57.00
2/10/2022Morgan StanleyLower TargetEqual Weight$60.00 ➝ $55.00
2/10/2022MizuhoLower Target$56.00 ➝ $55.00
2/9/2022BarclaysSet Target$54.00
2/8/2022JPMorgan Chase & Co.Set Target$57.00
2/8/2022The Goldman Sachs GroupSet TargetNeutral$51.00 ➝ $54.00
1/28/2022JPMorgan Chase & Co.Boost TargetNeutral$53.00 ➝ $57.00
1/14/2022BMO Capital MarketsBoost Target$60.00 ➝ $76.00
1/11/2022BarclaysSet Target$54.00
1/10/2022The Goldman Sachs GroupSet Target$51.00
1/7/2022Wells Fargo & CompanyBoost TargetOverweight$60.00 ➝ $65.00
1/5/2022Bank of AmericaUpgradeNeutral ➝ Buy$59.00 ➝ $70.00
1/4/2022The Goldman Sachs GroupSet Target$51.00
1/4/2022BarclaysSet Target$54.00
1/3/2022Sanford C. BernsteinBoost TargetMarket Perform$44.00 ➝ $65.00
12/29/2021The Goldman Sachs GroupSet Target$51.00
12/29/2021BarclaysSet Target$54.00
12/23/2021BarclaysSet Target$54.00
12/23/2021The Goldman Sachs GroupSet Target$51.00
12/20/2021CowenBoost TargetOutperform ➝ Outperform$56.00 ➝ $70.00
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$51.00
12/16/2021BarclaysSet Target$54.00
12/15/2021Leerink PartnersBoost TargetMarket Perform$52.00 ➝ $56.00
12/14/2021MizuhoBoost TargetNeutral ➝ Neutral$44.00 ➝ $56.00
12/14/2021Berenberg BankReiterated RatingHold$54.00
12/13/2021JPMorgan Chase & Co.Set Target$53.00
12/13/2021UBS GroupUpgradeNeutral ➝ Buy$52.00 ➝ $60.00
12/10/2021BarclaysBoost TargetEqual Weight ➝ Equal Weight$44.00 ➝ $54.00
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$60.00
11/29/2021JPMorgan Chase & Co.Boost TargetNeutral$42.00 ➝ $53.00
11/29/2021Morgan StanleyBoost TargetSell ➝ Equal Weight$50.00 ➝ $60.00
11/24/2021Truist FinancialBoost TargetBuy$43.00 ➝ $58.00
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$60.00
11/17/2021BarclaysSet Target$44.00
11/11/2021Independent ResearchUpgradeBuy$53.00
11/5/2021Cantor FitzgeraldReiterated RatingBuy$60.00
11/5/2021BenchmarkBoost TargetBuy$29.00 ➝ $45.00
11/5/2021JPMorgan Chase & Co.Set Target$42.00
11/3/2021BarclaysSet Target$44.00
11/3/2021Leerink PartnersLower TargetMarket Perform$50.00 ➝ $48.00
10/12/2021Morgan StanleyBoost TargetEqual Weight$45.00 ➝ $48.00
10/3/2021MizuhoReiterated RatingHold$43.00
9/20/2021Leerink PartnersBoost TargetMarket Perform$49.00 ➝ $50.00
9/14/2021Leerink PartnersReiterated RatingHold$49.00
9/13/2021JPMorgan Chase & Co.Boost TargetNeutral$40.00 ➝ $42.00
7/30/2021MizuhoBoost TargetNeutral$42.00 ➝ $43.00
7/29/2021The Goldman Sachs GroupSet Target$48.00
7/29/2021Morgan StanleyBoost TargetEqual Weight$42.00 ➝ $45.00
7/29/2021Royal Bank of CanadaSet Target$44.00
7/29/2021Leerink PartnersBoost TargetMarket Perform$47.00 ➝ $49.00
7/27/2021Truist FinancialInitiated CoverageBuy$43.00
6/17/2021Royal Bank of CanadaBoost TargetSector Perform$43.00 ➝ $44.00
6/15/2021Berenberg BankReiterated RatingNeutral$43.00
5/24/2021JPMorgan Chase & Co.Set TargetNeutral$40.00
5/24/2021The Goldman Sachs GroupSet TargetNeutral$45.00
5/13/2021The Goldman Sachs GroupReiterated RatingNeutral$45.11
5/12/2021MizuhoReiterated RatingBuy ➝ Neutral$42.00
5/10/2021Morgan StanleyBoost TargetEqual Weight$38.00 ➝ $42.00
5/6/2021MizuhoDowngradeBuy ➝ Neutral$42.00
5/5/2021Leerink PartnersBoost TargetMarket Perform$39.00 ➝ $43.00
5/5/2021JPMorgan Chase & Co.Boost TargetNeutral$36.00 ➝ $40.00
5/5/2021BarclaysBoost TargetEqual Weight$37.00 ➝ $40.00
4/7/2021Royal Bank of CanadaInitiated CoverageSector Perform$42.00
4/6/2021The Goldman Sachs GroupSet TargetNeutral$41.00
3/31/2021The Goldman Sachs GroupSet TargetNeutral$41.00
3/26/2021Leerink PartnersLower TargetMarket Perform$40.00 ➝ $39.00
3/23/2021Berenberg BankReiterated RatingNeutral$38.00
3/15/2021The Goldman Sachs GroupSet TargetNeutral$41.00
3/9/2021The Goldman Sachs GroupReiterated RatingNeutral$41.00
2/3/2021JPMorgan Chase & Co.Set TargetNeutral$36.00
2/3/2021DZ BankReiterated RatingHold ➝ Buy$41.00
2/3/2021Leerink PartnersLower TargetMarket Perform$44.00 ➝ $40.00
2/3/2021MizuhoLower TargetBuy$44.00 ➝ $42.00
1/29/2021Morgan StanleyLower TargetEqual Weight$40.00 ➝ $38.00
1/21/2021The Goldman Sachs GroupSet TargetNeutral$40.00
1/8/2021The Goldman Sachs GroupSet TargetNeutral$40.00
1/4/2021Royal Bank of CanadaSet TargetNeutral$42.00
12/29/2020Royal Bank of CanadaReiterated RatingNeutral$42.00
12/16/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$43.00 ➝ $42.00
12/11/2020The Goldman Sachs GroupSet TargetNeutral$40.00
12/4/2020BarclaysBoost TargetEqual Weight$35.00 ➝ $37.00
12/2/2020BarclaysSet TargetNeutral$35.00
12/2/2020Royal Bank of CanadaSet TargetBuy$43.00
12/2/2020The Goldman Sachs GroupSet TargetNeutral$40.00
11/19/2020The Goldman Sachs GroupInitiated CoverageNeutral$40.00
11/10/2020Sanford C. BernsteinInitiated CoverageMarket Perform$42.00
11/10/2020MizuhoBoost TargetBuy$43.00 ➝ $44.00
11/9/2020BarclaysReiterated RatingNeutral$35.00
11/9/2020JPMorgan Chase & Co.Set TargetNeutral$36.00
10/28/2020Leerink PartnersBoost TargetMarket Perform$42.00 ➝ $43.00
10/23/2020Truist FinancialInitiated CoverageBuy$42.00
10/16/2020Royal Bank of CanadaSet TargetBuy$43.00
10/12/2020Atlantic SecuritiesDowngradeOverweight ➝ Neutral$44.00 ➝ $39.00
9/29/2020Berenberg BankInitiated CoverageHold$38.00
9/15/2020MizuhoReiterated RatingBuy$43.00
9/9/2020Royal Bank of CanadaSet TargetBuy$43.00
7/30/2020Morgan StanleyBoost TargetEqual Weight$36.00 ➝ $42.00
7/29/2020UBS GroupBoost TargetNeutral$37.00 ➝ $39.00
7/29/2020Leerink PartnersBoost TargetMarket Perform$39.00 ➝ $42.00
7/28/2020MizuhoReiterated RatingPositive ➝ Buy$38.00
7/21/2020Morgan StanleyReiterated RatingHold$36.00
7/20/2020Royal Bank of CanadaReiterated RatingBuy$43.00
6/29/2020MizuhoInitiated CoverageBuy$38.00
6/26/2020Piper SandlerBoost Target$18.50 ➝ $24.00
6/16/2020Leerink PartnersInitiated CoverageMarket Perform$40.00
6/1/2020BarclaysLower Target$37.00 ➝ $35.00
6/1/2020JPMorgan Chase & Co.Lower TargetNeutral$37.00 ➝ $36.00
5/18/2020MizuhoReiterated RatingBuy$42.00
4/29/2020BarclaysBoost TargetEqual Weight$36.00 ➝ $37.00
4/27/2020Royal Bank of CanadaReiterated RatingBuy$44.00
4/26/2020MizuhoReiterated RatingBuy$42.00
4/2/2020Morgan StanleyLower TargetEqual Weight$43.00 ➝ $36.00
3/27/2020Royal Bank of CanadaLower TargetOutperform$46.00 ➝ $44.00
3/19/2020Cantor FitzgeraldReiterated RatingBuy$53.00
3/18/2020MizuhoReiterated RatingBuy$42.00
2/27/2020Standpoint ResearchUpgradeHold ➝ Buy
2/27/2020BarclaysInitiated CoverageEqual Weight$36.00
2/5/2020MizuhoInitiated CoverageBuy$42.00
1/29/2020Cantor FitzgeraldReiterated RatingBuy$53.00
1/28/2020JPMorgan Chase & Co.Reiterated RatingNeutral$37.00
1/6/2020Royal Bank of CanadaInitiated CoverageOutperform$46.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 107 very positive mentions
  • 86 positive mentions
  • 20 negative mentions
  • 10 very negative mentions
Mentions as of
5/24/2024
  • 77 very positive mentions
  • 24 positive mentions
  • 14 negative mentions
  • 1 very negative mentions
Mentions as of
6/23/2024
  • 85 very positive mentions
  • 38 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
7/23/2024
  • 86 very positive mentions
  • 73 positive mentions
  • 13 negative mentions
  • 3 very negative mentions
Mentions as of
8/22/2024
  • 65 very positive mentions
  • 60 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
Mentions as of
9/21/2024
  • 83 very positive mentions
  • 81 positive mentions
  • 26 negative mentions
  • 2 very negative mentions
Mentions as of
10/21/2024
  • 122 very positive mentions
  • 75 positive mentions
  • 19 negative mentions
  • 3 very negative mentions
Mentions as of
11/20/2024
  • 166 very positive mentions
  • 96 positive mentions
  • 14 negative mentions
  • 9 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 166 very positive mentions
  • 96 positive mentions
  • 14 negative mentions
  • 9 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $26.36
Low: $25.70
High: $26.49

50 Day Range

MA: $26.82
Low: $24.80
High: $29.66

52 Week Range

Now: $26.36
Low: $24.48
High: $31.54

Volume

116,162,070 shs

Average Volume

39,035,680 shs

Market Capitalization

$149.38 billion

P/E Ratio

35.62

Dividend Yield

6.65%

Beta

0.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Pfizer?

The following Wall Street analysts have issued reports on Pfizer in the last twelve months: Argus, Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Daiwa America, Daiwa Capital Markets, Evercore ISI, Guggenheim, Morgan Stanley, Sanford C. Bernstein, StockNews.com, TD Cowen, Truist Financial Co., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for PFE.

What is the current price target for Pfizer?

0 Wall Street analysts have set twelve-month price targets for Pfizer in the last year. Their average twelve-month price target is $32.14, suggesting a possible upside of 21.9%. Cantor Fitzgerald has the highest price target set, predicting PFE will reach $45.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $25.00 for Pfizer in the next year.
View the latest price targets for PFE.

What is the current consensus analyst rating for Pfizer?

Pfizer currently has 1 sell rating, 9 hold ratings, 5 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PFE, but not buy more shares or sell existing shares.
View the latest ratings for PFE.

What other companies compete with Pfizer?

Other companies that are similar to Pfizer include Johnson & Johnson, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb and Zoetis. Learn More about companies similar to Pfizer.

How do I contact Pfizer's investor relations team?

Pfizer's physical mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company's listed phone number is (212) 733-2323. The official website for Pfizer is www.pfizer.com. Learn More about contacing Pfizer investor relations.